Shilpa Pharma Lifesciences Ltd received CEP from EDQM for API, Ursodeoxycholic Acid

Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Ursodeoxycholic Acid.

Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones and to treat cholestatic forms of liver diseases including primary biliary cirrhosis. Ursodiol has been linked to rare instances of transient and mild serum aminotransferase elevations during therapy and to rare instances of jaundice and worsening of liver disease in patients with preexisting cirrhosis.

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 682.10 as compared to the previous close of Rs. 701.50. The total number of shares traded during the day was 31526 in over 2549 trades.

The stock hit an intraday high of Rs. 702.95 and intraday low of 676.55. The net turnover during the day was Rs. 21729530.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 ShilpaPharmaLifesciences CEP EDQM API UrsodeoxycholicAcid